Clinical trial
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With…
NCT00499993 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00499993 |
|---|---|
| Title | Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly |
| Official title | Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | lanreotide (Autogel formulation), duration of treatment 46-48 weeks |
| Enrollment | 63 |
| Start date | Jan 1, 2001 |
| Completion | May 1, 2003 |
| First posted | Jul 12, 2007 |
| Last update posted | Jan 15, 2019 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: